Chinese medicine as a resource for liver fibrosis treatment

Yibin Feng¹, Kwok-Fan Cheung², Ning Wang¹, Ping Liu³, Tadashi Nagamatsu⁴ and Yao Tong*¹

Abstract

Liver fibrosis is a condition of abnormal proliferation of connective tissue due to various types of chronic liver injury often caused by viral infection and chemicals. Effective therapies against liver fibrosis are still limited. In this review, we focus on research on Chinese medicines against liver fibrosis in three categories, namely pure compounds, composite formulae and combination treatment using single compounds with composite formulae or conventional medicines. Action mechanisms of the anti-fibrosis Chinese medicines, clinical application, herbal adverse events and quality control are also reviewed. Evidence indicates that some Chinese medicines are clinically effective on liver fibrosis. Strict quality control such as research to identify and monitor the manufacturing of Chinese medicines enables reliable pharmacological, clinical and in-depth mechanism studies. Further experiments and clinical trials should be carried out on the platforms that conform to international standards.

Background

Liver fibrosis is a condition of abnormal proliferation of connective tissue due to various types of chronic liver injury often caused by viral infection and chemicals. Hepatitis B viral (HBV) infection is the major cause of liver fibrosis in China, whereas hepatitis C viral (HCV) infection and alcohol are the main causes in the United States, Europe and Japan [1-4]. Liver fibrosis may progress into liver cirrhosis and other complications coupled with carcinogenesis [5,6]. The pathogenesis of liver fibrosis involves the activation of hepatic stellate cells (HSCs), the over-expression and over-secretion of collagens, and consequently an excessive accumulation of extracellular matrix (ECM) proteins [7]. Research has been focused on the management of liver fibrosis including the elimination of primary diseases, immunomodulation, suppression of hepatocyte inflammation, prevention of death and damage of hepatocytes, inhibition of over-secretion and accumulation of ECM proteins, promotion of ECM degradation, improvement of microcirculation and metabolism of liver and reduction of complications [8]. The reversal of liver fibrosis and even cirrhosis has been documented [9].

Complementary and alternative treatments of liver fibrosis have been under active research worldwide [10-12]. In Chinese medicine, liver fibrosis is thought to be caused by ‘poor blood circulation, toxin stagnation and a deficiency
of healthy energy’ (dysregulated metabolism). Thus, Chinese medicine therapy to treat liver fibrosis is mainly based on reducing blood stagnation, resolving stasis, eliminating toxins and enhancing body immunity.

This review aims to provide an overview on the types of Chinese medicines used to treat liver fibrosis.

**Chinese medicines used to treat liver fibrosis**

**Compounds and extracts**

Around 20 compounds or extracts from Chinese medicines have been reported to have liver protective and anti-fibrotic effects. Various studies on their chemistry and pharmacology as well as clinical trials have been carried out to study these compounds or extracts. Table 1 summarizes those with liver protection and anti-fibrotic effects demonstrated in various research reports [13-68].

**Composite formulae**

More than ten composite formulae for liver fibrosis have been reported [69-108]. Table 2 summarizes traditional composite formulae such as Yinchenhao Tang, Xiao Chaithu Tang, Buzhong Yiqi Tang and Renshen Yangrong Tang as well as modern formulae such as Fufang Jinsane, Danshen Taixin Tang, Ershen Zechu Tang, Buqi Jianzhong Tang, Fangji Tang, Handan Gane, Ganzhifu and Fucheng Huaya.

**Combination therapy**

Studies [109-118] show that combination therapy improves clinical anti-fibrotic effects by using a single compound with composite formulae or Chinese medicines with conventional medicines (Table 3).

**Action mechanisms of Chinese medicines in treating liver fibrosis**

**Inhibition of viral replication**

HBV and HCV infections account for most liver cirrhosis and primary liver cancer worldwide [6]. Certain Chinese medicines are anti-HBV and anti-HCV. Berberine markedly reduces viral production in vitro but is toxic to host cells [51]. Artemisinin and artesunate strongly inhibit viral production at concentrations that do not affect host cell viability; artesunate and lamivudine exhibit synergistic anti-HBV effects [51]. Another study shows that ascu-cubin inhibits HBV replication [63]. Nobiletin, the active ingredient of *Citrus unshiu* peel, has anti-HCV effects [94]. Clinical studies show that oxymatrine [28] is effective in reducing hepatitis B viral replication in patients with chronic hepatitis B. *Xiao Chaithu Tang* enhances production of interferon-gamma (IFN-γ) and antibodies against hepatitis B core and e antigen by peripheral blood mono-nuclear cells (PBMC) in patients with chronic hepatitis [82]. *Handan Gane* inhibits viral DNA replication in patients with decompensated cirrhosis thereby leading to clinical improvement [102].

**Immunomodulation action**

*Buzhong Yiqi Tang* and *Renshen Yangrong Tang* demonstrate immunomodulation effects [91]. In a study on porcine serum-induced liver fibrosis in rats [92], Interleukin 13 (IL-13) levels are positively correlated with hydroxyproline (Hyp) contents in the liver. *Buzhong Yiqi Tang* and *Renshen Yangrong Tang* significantly suppress the increase of hepatic Hyp, while *Xiao Chaithu Tang* does not. Short-term and long-term studies [93] show that *Renshen Yangrong Tang* is effective in liver fibrosis. Further studies find that *Renshen Yangrong Tang* inhibits HCV infection, and that Gomisin A, an active component in the formula’s *Schisandra* fruit, exhibits protective effects on immunological hepatic hepatopathy [94].

**Anti-oxidation and anti-inflammation actions**

*Salvia miltiorrhiza* (*Danshen*) extract [13] improves serum superoxide dismutase (SOD) activity and reduces malondialdehyde (MDA) content in both carbon tetrachloride (CCl₄) and dimethylsulfoxide (DMN) induced hepatic fibrosis rat models. *Salvia miltiorrhiza* extract [18] increases hepatic glutathione levels and decreases peroxidation products in a dose-dependent manner. Taurine [27,28] reduces oxidative stress and prevents progression of hepatic fibrosis in CCl₄-induced hepatic damaged rats and inhibits transformation of the hepatic stellate cell (HSC). In chronic ethanol-induced hepatotoxicity or CCl₄-induced rat liver fibrosis, *Panax notoginseng* (*Tianqi*) extract or total saponin extracted from *Panax notoginseng* reduces the generation of MDA, scavenges free radicals, increases liver and serum SOD content and reduces the accumulation of body lipid peroxide [44-46]. *Ginkgo biloba* (*Yinxing*) extract [49,50] and berberine [54,56,60] exhibit anti-oxidation effects and suppress nuclear factor κB (NF-κB) in rats or cell culture. *Yinchenhao Tang* is used to treat liver fibrosis and portal hypertension through suppressing the activated HSC function by genipin, an absorbed form of its component, in CCl₄-or pig-serum- induced rat liver fibrosis [72]. Lin *et al.* [68] find that the hepatoprotective effect of *Solanum nigrum* Linn extract on CCl₄-induced liver fibrosis is achieved through blocking oxidative stress. *Xiao Chaithu Tang* [76,83,85] whose active components baikalin and baikalein function as a potent fibrosis suppressant via the inhibition of the oxidative stress in hepatocytes and HSC. *Handan Gane* [99] is effective in protecting against liver fibrosis by inhibiting lipid peroxidation in hepatocytes and HSC *in vivo*.

**Regulation of cytokines, collagen metabolism and inhibition of HSC**

The fibrogenic process is regulated by TGF-β1 and the specific blockade of TGF-β1/Smad3 signalling may therapeutically intervene in the fibrosis of various tissues [119]. Most of the Chinese medicines listed in Tables 1 and 2
Table 1: Anti-fibrosis effect of compounds or extracts derived from Chinese medicines

| Compounds or extracts and major references | Pharmacological actions and clinical indications | Botanic source |
|-------------------------------------------|-------------------------------------------------|----------------|
| **Salvia miltiorrhiza** Extract & SA-B [13-18] | Reduce ALT and AST activities, inhibit protein expressions of TGF-β1, type I collagen and Smad3, anti-oxidation, down-regulate TGF-β1, TIMP-1 gene expression and MAPK activity, anti-nitric oxide, anti-apoptosis, apply to CHB patients | Root of Salviae miltiorrhiza Bge. |
| **Glycyrrhizin** [19-26] | Reduce ALT and AST activities, inhibit NF-κB binding activity, down-regulate smurf2 gene expression, apply to CHC patients and prevent hepatocarcinoma in patients with HCV-associated cirrhosis | Rhizome of Glycyrrhiza uralensis Fisch., Glycyrrhiza inflata Batal. or Glycyrrhiza glabra L. |
| **Tetrandrine** [27-32] | Down-regulate c-fos and c-jun gene expression, anti-nitric oxide, up-regulate Smad7 gene expression, apply to CHB patients, down-regulate NF-κB signalling cascade and biomarker such as ICAM-1 and α-SMA | Root of Stephaniae tetrandrae S. Moore |
| **Matrine & Oxymatrine** [33-35] | Inhibit PDGF and TGF-β1 actions, inhibit HBV-DNA, improve liver function in patients with CHB or CHC patients | Root of Sophorae flavescentis Ait. |
| **Taurine** [36,37] | Inhibit TGF-β1 action, collagen formation in M cell culture system, reduce oxidative stress | Calculus Bovis |
| **Tetramethylpyrazine (Chuanxiongzine) [38]** | Anti-oxidation, synergic anti-hepatic fibrosis effect with rehin, apply to CHB patients | Rhizome of Ligusticum chuanxiong Hort. |
| **Rehin, emodin** [39-41] | Inhibit TGF-β1 expression, anti-HSC proliferation | Root and Rhizome of Rheum palmatum L., Rheum tanguticum Maxim. Ex Balf. or Rheum officinale Baill. |
| **Curcumin** [42,43] | Anti-oxidative effect, activate PPARγamma to reduce cell proliferation, induce apoptosis and suppress ECM gene expression in vitro and in vivo | Rhizome of Curcumae longa L. |
| **Panax Notoginseng saponin and its water-extract** [44-46] | Reduce AST and ALT, increase liver and serum SOD, reduce serum liver fibrosis markers levels, prevent liver fibrosis and hepatic microvascular dysfunction in liver fibrosis rats | Root of Panax notoginseng (Burk)F.H. Chen |
| **Cordyceps polysaccharide** [47,48] | Increase CD4/CD8 T lymphocytes ratio and decrease HA and PC III, inhibit TGF-β1 and PDGF expressions, reduce AST and ALT, apply to CHB patients | The complex of the stroma of the fungus Cordiceps sinensis (berk.)Sacc. and larva of caterpillar on which the fungus grows |
| **Ginkgo biloba extract** [49,50] | Reduce ALT and AST, anti-oxidation, suppress NF-κB activation, inhibit TGF-β1 and collagen gene expression in rats | Leaves of Ginkgo biloba L. |
| **Artemisinin/artesunate** [51] | As inhibitors of hepatitis B virus production | Aerial part of Artemesia annua L. |
| **Berberis aristata fruit extract and berberine** [52-62] | Reduce AST and ALT, anti-oxidation, suppress expression of NF-κB, α-SMA, TGF-β1, anti-liver cancer, induce apoptosis in cancer cell lines and animal models | Rhizome of Coptis chinensis French., Coptis teeta Wall., Coptis japonica Makino., other genus Berberis |
| **Aucubin** [63,64] | Reduce AST and ALT, against HBV replication, suppress NF-κB activation in cell or animal models. | Ripe seed of Plantago asiatica L. |
| **Ganoderma lucidum extract & Ganoderma polysaccharide** [65,66] | Reduce AST, ALT, ALP, Tbil and the collagen content in rats with cirrhosis induced by biliary obstruction in rats, inhibit HSCs cells proliferation through blocking PDGFIR phosphorylation | Ganoderma lucidum |
| **Gypenoside** [67] | Inhibits HSCs proliferation, arrest HSC cells at G1 phase, inhibit the signal pathway of PDGF-Arc-p70 and down-regulate of cyclin D1 and D3 expression | Gynostemma pentaphyllum |
| **Solanum nigrum Linn extract** [68] | Reduce AST, ALT, ALP, Tbil, modulate GSTs and SOD, repress the production of free radicals | Solanum nigrum Linn |
Table 2: Anti-fibrosis effect of composite formulae

| Composite formulae and major references | Pharmacological actions and clinical indications | Compositions of formulae |
|----------------------------------------|-------------------------------------------------|-------------------------|
| Yinchenhao Tang [69-78]                | Induce HSCs apoptosis, inhibit HSCs activation, reduce collagen deposition and α-SMA and decrease the serum level of HA, apply to postoperative biliary atresia patients and icteric patients with cirrhosis | **Herba Artemisie Scoparionae**, **Radix et Rhizoma Rhei**, **Fructus Gardeniae** |
| Xiao Chaifu Tang [79-90]              | Inhibit TGF-β1 and PDGF expressions, regulate MMPs/TIMPs balance, increase IL-12 production, suppress HSC activation, apply to CHC and CHB patients | **Radix Bupleuris**, **Radix Scutellariais**, **Rhizoma Pinelliae**, **Radix Ginseng**, **Fructus Jujubae**, **Radix Glycyrrhizae** |
| Buzhong Yiqi Tang [91,92]             | Immunoregulation, inhibit TGF-β1 and IL-13 production, apply to CHC patients | **Radix Astragali**, **Radix Glycyrrhizae**, **Radix Ginseng**, **Radix Angelicae Sinensis**, **Pericarpium citri reticulatum**, **Rhizoma Cimicifugae**, **Radix Bupleuri**, **Radix Atractylodis macrocephalae** |
| Renshen Yangrong Tang [92-94]         | Immunoregulation, inhibit TGF-β1 and IL-13 production, apply to CHC patients | **Radix Astragali**, **Radix Angelicae sinensis**, **Cortex Cinnamomi**, **Radix Glycyrrhizae**, **Pericarpium citri reticulatum**, **Rhizoma Atractylodis macrocephalae**, **Radix Ginseng**, **Radix Paeoniae alba**, **Radix Rehmanniae**, **Fructus Schisandrae chinensis**, **Poria**, **Cortex et Radix Polygalae** |

**Fufang jinsan E** [95]               | Inhibit TGF-β1 and Smad3, Up-regulate Smad7 in liver fibrotic rats | **Radix Curcumae**, **Rhizoma Sparganii**, **Rhizoma Curcumae** |
| **Denshen Taoxiang Tang** [96]       | Anti-ascites, regulate urine sodium concentration in liver fibrotic mouse | **Radix Salviae Miltiorrhizae**, **Semen Persicae**, **Rhizoma Chuanxiong** |
| **Ershen Zezhu Tang** [96]            | Anti-ascites, regulate urine sodium concentration in liver fibrotic mouse | **Radix Codonopsis**, **Radix Salviae miltiorrhizae**, **Rhizoma Atractylodis macrocephalae**, **Rhizoma Alismatis** |
| **Buqi jianzhong Tang** [97,98]       | Diuretic effect, increase excretion Na+, reduce GPT and GOT, apply to cirrhosis ascites | **Largehead Atractylodis Rhizoma**, **Hoelen**, **Aurantii Nobilis Pericarpium**, **Radix Ginseng**, **Radix Scutellariais**, **Magnolia Bark**, **Alisma Rhizoma**, **Radix Ophiopogonis**, **Atractylodis Rhizoma** |
| **Fangji Tang** [97,98]               | Diuretic effect, increase excretion Na+, reduce GPT and GOT, apply to cirrhosis ascites | **Sinomeni Caulis Et Rhizoma**, **Moris Cortex**, **Hoelen Preilla Herba**, **Saussureae Radis** |
| **Handan Garle** [99-102]             | Anti-oxidation, collagenolytic effect, regulate MMPs/TIMPs balance, apply to CHB patients | **Radix Sophorae Fлавесцентis**, **Radix Salviae miltiorrhizae**, **Radix Paeoniae**, **Radix Astragali**, **Folium Ginkgo** |
| **Ganzhifu** [103]                   | Anti-oxidation, reduce collagen, anti-liver fibrosis in liver fibrotic rats | **Rhizoma Zingiberis**, **Ramulus Cinnamomi**, **Radix Aconi Lateralis preparata**, **Radix Astragali**, **Radix Bupleuri**, **Fructus Aurantii**, **Rhizoma Atractylodis macrocephalae**, **Radix Glycyrrhizae** |
| **Fuzheng Huay** [104-108]            | Significantly decrease HA, LM, P-III-P and IV-C content, improve serum Alb, ALT, AST, GGT, LM, HA, Hyp and ration of BCAA/AAA in animals and CHB patients. Inhibit HSCs activation via FN/integrin signaling. | **Radix Salviae miltiorrhizae**, **Cordyceps mycelia extract**, **Semen Persicae**, **Gynostemma Pentaphyllammak**, **Pollen Pini**, **Fructus schisandrae chinensis** |

*exhibit in vitro and in vivo inhibitory effects on TGF-β1. Salvianolic acid B (SA-B) inhibits HSC proliferation and collagen production and decreases the cellular TGF-β1 autocrine and Mitogen-Activated Protein Kinase (MAPK) activity, which may be the anti-fibrosis mechanism of SA-B [14,17]. Paclitaxel, a compound isolated from Taxus brevifolia, suppresses the TGF-β1 signalling pathway between biliary epithelium cells and myofibroblasts and reduces collagen synthesis [120]. Yinchenhao Tang [71] regulates platelet-derived growth factor (PDGF)-BB-dependent signalling pathways of HSC in primary culture and attenuates the development of liver fibrosis induced by thioacetamide in rats. Among the components of Yinchenhao Tang, 3-methyl-1,6,8-trihydroxyantraquinone (emodin) derived from Rhei rhizoma is the most active compound [72]. Genipin, a metabolite derived from Yinchenhao Tang, suppresses wound-induced cell migration and proliferation and decreases collagen type I, TGF-β1 and α-smooth muscle actins (α-SMA) mRNA and protein expression [76]. Chen et al. [67] demonstrate that Gypenosides inhibits PDGF-induced HSCs proliferation through inhibiting the signalling pathway of PDGF-Akt-p70S6K and down-regulating cyclin D1 and D3 expression. Another study shows that ganoderic acids and ganoderenic acids in Ganoderma lucidum (Lingzhi) extract significantly inhibit the proliferation of HSCs by attenuating the*
blockade of PDGFR phosphorylation [66]. Chen et al. [88] show that 0.5 g/kg/day of Xiao Chaihu Tang significantly reduces the serum level of the N-terminal pro-peptide of collagen type III (PIII NP) and the mRNA expression of TGF-β1 and PDGF in a rat bile duct ligated model.

**Anti-apoptosis in hepatocyte and inducement of apoptosis in HSC**

Yamamoto et al. [73] find that Yinchenhao Tang inhibits hepatocyte apoptosis induced by TGF-β1 in vitro. Another study [74] demonstrates that pre-treatment with Yinchenhao Tang markedly suppresses liver apoptosis/injury. Genipin, which is a principal ingredient of Yinchenhao Tang, suppresses Fas-mediated apoptosis in primary-cultured murine hepatocytes in vitro [73]. The resistance to Ca2+-induced mitochondrial permeability transition (MPT) is enhanced in liver mitochondria of genipin-treated mice [74]. These results suggest that the anti-apoptotic activity of genipin via the interference with MPT is a possible mechanism for the therapeutic effects of Yinchenhao Tang and that Yinchenhao Tang and its ingredient genipin protect hepatocyte from liver apoptosis/injury. Conversely, activated HSC plays a pivotal role in hepatic fibrosis. HSC apoptosis is involved in the mechanisms of spontaneous resolution of rat hepatic fibrosis, and the agent that induces HSC apoptosis has been shown to reduce experimental hepatic fibrosis in rats [121]. Considerable interest has been generated in uncovering the molecular events that regulate HSC apoptosis and discovering drugs that can stimulate HSC apoptosis in a selective manner. Ikeda et al. [75] find that Yinchenhao Tang induces HSC apoptosis in a time- and concentration-dependent manner as judged by the nuclear morphology, quantitation of cytoplasmic histone-associated DNA oligonucleosome fragments and caspase-3 activity. Thus, the induction of HSC apoptosis may be the mechanism whereby Yinchenhao Tang treats hepatic fibrosis. Tetrandrine [29] also induces apoptosis of T-HSC/Cl-6 cells and induces the activation of caspase-3 protease and subsequent proteolytic cleavage of poly (ADP-ribose) polymerase.

**Synergistic effects on liver fibrosis and carcinogenesis**

Berberine derived from berberis markedly reduces viral production in vitro [51]. In liver damage induced by paracetamol or CCl4, *Berberis aristata* fruit extract and berberine, its principal ingredient, show hepatoprotective action [52,53]. Berberine also exhibits antioxidative effects on tert-butyl hydroperoxide-induced oxidative damage in rat liver [54] and in the lipopolysaccharide (LPS) plus ischemia-reperfusion model [55]. Berberine abolishes acetaldehyde-induced NF-κB activity and cytokine production in a dose dependent manner, suggesting the potential role of berberine to treat alcoholic liver disease (ALD) [56]. In the rat liver fibrosis induced by multiple hepatotoxic factors (CCl4, ethanol and high cholesterol), the serum levels of ALT and AST and the hepatic content of MDA and Hyp are markedly decreased, while the activity of hepatic SOD is significantly increased in berberine-treated groups in a dose-dependent manner. In addition, histopathological changes, such as steatosis, necrosis and myofibroblast proliferation, are reduced and the expression of α-SMA and TGF-β1 is significantly down-regulated in the berberine-treated groups [57].

---

**Table 3: Anti-fibrosis effect of combinations of single compound and formulae or Chinese medicines and conventional medicines**

| Combination of drugs and major references                                      | Clinical indications and pharmacological actions or side effects                                                                 |
|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| ITF-α. injection + glycyrrhizin (Stronger Neo Minophagen C) injection [109]     | CHC patients. With IFN therapy, ALT levels did not decrease more than 50%, while with IFN combined with SNMC therapy, ALT levels decreased approximately 70% in all patients (one became normal), but no other parameters were changed. |
| Ursodeoxycholic acid P.O + glycyrrhizin P.O [110]                             | CHC patients belong to interferon-resistant or unstable patients. Improving liver-specific enzyme abnormalities: AST, ALT and gamma-glutamyl transpeptidase, no change HCV-related factors or liver histology compared with control. |
| Matrine injection + Xiao Chaihu Tang P.O [111]                                | Liver fibrosis patients. Combination therapy improves AST, ALT and reduces HA, LN, CIV, TGF-β1 and TNF-α.                     |
| IFN-γ or IFN-α. injection + Xiao Chaihu Tang (Sho-saiko-to) P.O [112-115]      | CHB patients. Combination therapy improves AST, ALT, Tbil and has synergistic anti-fibrosis in biochemical parameters, but IFN and/or Sho-saiko-to may also induce acute interstitial pneumonitis. |
| Tiopronin P.O + Xiao Chaihu Tang P.O [116]                                     | CHB patients. Synergistic effects in improving liver functions and fibrotic factors.                                          |
| Lamivudine + Radix Salviae Militorrhizae [117]                                | CHB patients. Treatment with both drugs was better than one and more effective than the control group in parameters of liver function and liver fibrosis. |
| Busen Granule (BSG) P.O + Marine Injection (MI) [118]                         | CHB patients. Combined treatment of BSG and MI was better than Lamivudine group in one year therapeutic course.               |
Clinically, berberine has been used in Japan to alleviate hypertyraminemia in patients with liver cirrhosis [58]. Berberine possesses anti-tumor effects in rats and mice with chemical-induced liver cancer [59] and anti-invasion in human lung cancer cell lines [60]. The mechanism may be related to its anti-inflammation effects [60,61]. The inhibitory effects of two different doses of berberine in human liver cancer HepG2 cell lines display different effects: in HepG2 cells treated with 24.0 mg/L of berberine, an increase in the sub G0 phase that indicates cell death is observed in cell cycle analysis with flow cytometry, however, there is no significant increase in sub G0 in HepG2 cells treated with 4.0 mg/L of berberine [62]. These results demonstrate that the dosage of berberine is a meaningful factor in liver diseases treatment. Composite formulae, such as Xiao Chaihu Tang, not only inhibit viral replication, ameliorate inflammation and enhance regeneration of hepatic cells, but also inhibit HSC proliferation, suppress intra- and extra-cellular secretion, decrease the secretion of collagen and promote its degradation and re- suppression intra- and extra-cellular secretion, decrease the replication, ameliorate inflammation and enhance regeneration of hepatic cells, but also inhibit HSC proliferation, suppress intra- and extra-cellular secretion, decrease the secretion of collagen and promote its degradation and re-absorption [79-90]. Shimizu et al. [83] show that Xiao Chaihu Tang functions as a potent anti-fibrosis agent via the inhibition of oxidative stress in hepatocytes and HSCs and that its active components are baicalin and baicalein. It should be noted that baicalin and baicalein are flavonoids with chemical structures very similar to silybinin which possess anti-fibrogenic activities. Several composite formulae have been used to improve asides induced by hepatic cirrhosis in chronic hepatitis B (CHB) or chronic hepatitis C (CHC) patients. We demonstrate that Buqi Jianzhong Tang and Fangji Tang increase Na+ excretion and urine volume and reduce GOT and GPT in rats with CCl4-induced liver damage [89,98]. Most of the Chinese medicines in Tables 1 and 2 reduce serum enzymes, i.e. aspartate transaminase (AST) and alanine transaminase (ALT). A study with multivariate analysis demonstrates that the mode of therapy and ALT levels are significant factors affecting HCC development [26]. Glycyrrhizin administered as Stronger Neo Minophagen C (SNMC) and Xiao Chaihu Tang exhibit this effect [24-26,90] in long-term clinical trials. Considered to possess anti-carcinogenic properties, Xiao Chaihu Tang inhibits chemical hepatocarcinogenesis in animals, acts as a biological response modifier and suppresses the proliferation of hepatoma cells by inducing apoptosis and arresting the cell cycle. Among the active components of Xiao Chaihu Tang, baicalin, baicalein and saikosaponin have the ability to inhibit cell proliferation [90].

**Efficiency and safety of Chinese medicines in treating liver fibrosis**

**Efficacy**

Some anti-fibrosis Chinese medicines, such as Salvianolic acid B (SA-B), tetrandrine and oxymatrine, are clinically effective. SA-B reverses liver fibrosis in chronic hepatitis B patients. SA-B reduces the serum HA content and decreases the overall serum fibrosis markers better than IFN-γ [14]. A multi-centre, randomized, double-blind, placebo-controlled clinical trial shows that oxymatrine effectively reduces the DNA replication of HBV [34,35] and the therapeutic effect is even stronger when used together with Xiao Chaihu Tang [110]. A double-blind, randomized, placebo-controlled phases I/II trial of intravenous glycyrrhizin for the treatment of chronic hepatitis C shows that glycyrrhizin lowers serum ALT and that the treatment has no effect on the RNA levels of HCV [23]. Long-term clinical trials in Japan and the Netherlands demonstrate that interferon non-responder patients with chronic hepatitis C and fibrosis stage 3 or 4 have a reduced incidence rate of HCC after glycyrrhizin therapy normalizes ALT levels [24,25].

In China and Japan, many composite formulae are used to treat liver fibrosis and cirrhosis (Table 2) and the pharmacological effects and mechanisms have been demonstrated [69-94]. Experimental and clinical studies show that Handan Ganle is effective [99-102]. Fuzheng Huayu, another modern formula, has also been intensively studied [104-107]. The results suggest that Fuzheng Huayu's anti-fibrosis effects may be associated with the inhibition of liver collagen production [104]. Further study reveals that the conditioned medium from activated HSC stimulates the quiescent HSC proliferation and type I collagen secretion and that the drug serum inhibits this stimulating action and vascular endothelial growth factor (VEGF) secretion from the activated HSC. Fuzheng Huayu acts effectively against the autocrine activation pathway of HSC [105].

A recent study demonstrates the action of Fuzheng Huayu against HSC activation via the fibronectin/integrin-β1 signalling pathway [107]. Another study shows that Fuzheng Huayu alleviates liver fibrosis without any adverse events [106]. A systematic review analyzes the efficacy and safety of Fuzheng Huayu in treatment of CHB fibrosis [108] based on clinical trials with placebo and/or random control (other positive Chinese medicines and conventional drugs). Seven studies on Fuzheng Huayu in the treatment of CHB fibrosis (total 590 cases) are included in the systematic review. This systematic review concludes that Fuzheng Huayu has significant improvement of serum fibrosis index and pathology of liver biopsy (class S in fibrosis) without observable adverse events, although some included studies are of low quality and are small randomized clinical trials.

The combined therapy with ursodeoxycholic acid and glycyrrhizin is safe and effective in improving liver-specific enzyme abnormalities, and may be an alternative to interferon in chronic hepatitis C viral infection, especially for
The antiviral efficacy of Bushen granule (BSG) coupled with marine injection (MI) to treat chronic hepatitis B was more effective than lamivudine treatment [118]. Other reports of therapeutic value gained through combining conventional and Chinese medicines can be found in Table 3[112-117].

Safety
There have been reports on adverse events and hepatotoxicity caused by herbal medicines [122]. Xiao Chaihu Tang, used alone or in combination with interferon, may induce acute interstitial pneumonia in patients with chronic active hepatitis [113,114]. Glycyrrhizin injection may induce fatal biliary cirrhosis [123]. A one-year study demonstrates that Chinese medicines caused hepatotoxicity in patients with chronic hepatitis B [124]. Some of hepatic veno-occlusive diseases have been ascribed to toxicity of herbs; however, the toxic compounds remain to be determined. Hepatic veno-occlusive disease may result from pyrrolizidine alkaloids which are found in numerous plants worldwide. Systematic toxicological knowledge of Chinese medicines is available [125].

Adverse events in the cases of herbal toxicity are in fact very complex. The fatal biliary cirrhosis case [123] was a

---

**Figure 1**

**Research chart of Chinese medicines for liver fibrosis.** The re-evaluation involved in pharmaceutical and medical research including herb quality control, mechanism study and clinical trial will be carried out on standardized international platforms.
Evidence against Chinese medicines

While ample evidence supports Chinese medicines in treating liver fibrosis, some recent reviews on clinical trials did not find significant effects. Levy et al. [126] review the use of silymarin, glycyrrhizin, Xiao Chaihu Tang, Phyllanthus amarus, Picrorrhiza kurrooa, Compound 861, CH-100 and LIV.52 used to treat chronic liver diseases. Dhiman et al. [127] review Phyllanthus, Silibum marianum (milk thistle), glycyrrhizin and LIV.52 used to treat liver diseases. However, neither review recommends the use of herbal medicines to treat chronic liver diseases.

SA-B, Glycyrrhizin, Xiao Chaihu Tang and Yinchenhao Tang are used to treat chronic liver diseases in China and Japan. The major active herb is coptis, of which berberine is the major active component [128]. According to Chinese medicine theory, we use coptis to treat various liver diseases and cancer in Hong Kong [129]. We also propose to replace bear bile with coptis in Chinese medicine practice [130].

Further studies on pharmacological actions and clinical efficacies of the anti-fibrosis effects of Chinese medicines are warranted. Systematic reviews to evaluate clinical studies on the efficacy and safety of Chinese medicines are also necessary. An exemplifying strategy for these studies is demonstrated in Figure 1.

Conclusion

Evidence indicates that some Chinese medicines are clinically effective in treating liver fibrosis. Strict quality control of Chinese medicines is critical [131] for pharmacological, clinical and in-depth mechanism studies [132]. Experiments and clinical trials should be carried out on the platforms that conform to international standards [133].

Abbreviations

ECM: extracellular matrix; HSC: hepatic stellate cell; CAM: complementary and alternative medicine; SA-B: salvianolic acid B; HBV: hepatitis B virus; HCV: hepatitis C virus; CHB: chronic hepatitis B; CHC: chronic hepatitis C; AST (= GOT): aspartate aminotransferase; ALT (= GPT): alanine aminotransferase; TGF-β1: transforming growth factor beta 1; Smad3: Smad family member 3; Smad7: Smad family member 7; smurf2: Smad ubiquitination regulator factor 2; TIMP: tissue inhibitors of metalloproteases; MMP: matrix metalloprotease; MPK: mitogen-activated protein kinase; NF-κB: nuclear factor-κB; PDGF: platelet-derived growth factor; PPARgamma: proliferator-activated receptor gamma; SOD: superoxide dismutase; Hyp: hydroxyproline; HA: hyaluronic acid; α-SMA: α-smooth muscle actins; IFN-γ: interferon-gamma; IFN-α: interferon-alpha; LN: laminin; PCIII: type III procollagen; CIV: type IV collagen; Tbi: total bilirubin; TNF-α: tumor necrosis factor alpha; PIINP: the N-terminal pro-peptide of collagen type III; MPT: mitochondrial permeability transition; Alb: albumin; BCAA: branched chain amino acid; AAA: aromatic amino acid; FN/integrin: fibronectin (FN)-integrin-5β1 complex.

Competing interests

Fuzhen Huayu is a herbal product developed by PL’s institution at the Shanghai University of Traditional Chinese Medicine. The authors declare that they have no competing interests for other Chinese medicines discussed in the present study.

Authors’ contributions

YBF and YT conceived the study, interpreted the data and revised the manuscript. YBF retrieved and analyzed the data and drafted the manuscript. KFC and NW retrieved the data from Chinese journals and translated them into English. PL and TN supervised some of the experiments. All authors read and approved the final version of the manuscript.

Acknowledgements

The study was financially supported by grants from the Research Council of the University of Hong Kong (Project Codes: 10208005 and 10400413), the University Grants Committee (UGC) of Hong Kong (Project Code: 764708PM), the Pong Ding Yuen Endowment Fund for Education and Research in Chinese-Western Medicine (Project Code: 20005274) and the Government-Matching Grant Scheme (4th Phase, Project Code: 20740314). The authors would like to thank Prof SP Lee and Dr GKK Lau for their assistance in revising the manuscript.

References

1. Yuen MF, Lai CL: Natural history of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2000, 15(Suppl):E20-4.
2. Seeff LB, Hoofnagle JH: The national institutes of health consensus development conference management of hepatitis C 2002. Clin Liver Dis 2003, 7:261-87.
3. Kolke K: Antiviral treatment of hepatitis C: present status and future prospects. J Infect Chemother 2006, 12:227-32.

Page 8 of 11

(page number not for citation purposes)
26. Wang ZR, Chen XM, Li DG: Tetrandrine inhibits expressions of c-fos and c-jun mRNA in fibrosis liver of rats. *Shanghai Xueyuan Yibing Zazhi* 2006, 26:332-4.

27. Wang H, Chen XP, Qiu FZ: Tetrandrine increased hepatic expression of nitric oxide synthase type II in cirrhotic rats. *World J Gastroenterol* 2004, 10:1923-7.

28. Zhao YZ, Kim JF, Park EJ, Lee SH, Woo SW, Ko G, Sohn DH: Tetrandrine induces apoptosis in hepatic stellate cells. *Phytother Res* 2004, 18:306-9.

29. Chen YW, Li DG, Wu JX, Chen YW, Lu HM: Tetrandrine inhibits activation of rat hepatic stellate cells stimulated by transforming growth factor-beta in vitro via up-regulation of Smad 7. *J Ethnopharmacol* 2005, 100:299-305.

30. Hsu YC, Chiu YT, Lee CY, Wu CF, Huang YT: Anti-fibrotic effects of tetrandrine on bile-duct ligated rats. *Can J Physiol Pharmacol* 2006, 84:967-76.

31. Hsu YC, Chiu YT, Cheng CC, Wu CF, Lin YL, Huang YT: Anti-fibrotic effects of tetrandrine on hepatic stellate cells and rats with liver fibrosis. *J Gastroenterol Hepatol* 2007, 22:99-111.

32. Zhang JP, Zhang M, Zhou JP, Liu FT, Zhou B, Xie WF, Guo C: Anti-fibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats. *Acta Pharmacol Sin* 2001, 22:183-6.

33. Chen YY, Mao BY, Jiang JH: Relationship between serum load of HBV-DNA and therapeutic effect of oxymatrine in patients with chronic hepatitis B. *Zhongguo Zhongyi Jiehe Za Zhi* 2002, 23:335-6.

34. Mao YM, Zeng MD, Lu LG: Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo-controlled, multicenter clinical study. *World J Gastroenterol* 2004, 10:3269-73.

35. Kato J, Ido A, Hasukue S, Uto H, Hori T, Hayashi K, Murakami S, Terao A, Tsubouchi H: Transforming growth factor-beta-induced stimulation of formation of collagen fiber network and anti-fibrotic effect of taurine in an in vitro model of hepatic fibrosis. *Hepatol Res* 2004, 30:34-41.

36. Miyazaki T, Karube M, Matsuzaki Y, Ikegami T, Doy M, Tanaka N, Bosucare B: Taurine inhibits oxidative damage and prevents fibrosis in carbon tetrachloride-induced hepatic fibrosis. *J Hepatol* 2005, 43:17-25.

37. Chen ZZ, Wang H: Inhibitory Effects of tetramethylpyrazine on experimental hepatic fibrosis in rats. *Zhong Yi Jiehe Ganzh Zazhi* 1997, 7:156-9.

38. Tan LX, Li XS, Liu QZ, Liu LY: Effects of combination therapy of rehmin and tetramethylpyrazine on experimental hepatic fibrosis induced by tetrachloride. *Zhongguo Ganzhongg Zazhi* 2004, 12:692-9.

39. Zhan Y, Li D, Wei H, Wang Z, Huang X, Xu Q, Lu H: Emodin on hepatic fibrosis in rats. *Chin Med (Engl)* 2000, 11:599-601.

40. Zhan YT, Liu B, Li DG, Bi CS: Mechanism of emodin for anti-fibrosis of liver. *Zhonghua Ganzhongg Za Zhi* 2004, 12:245-6.

41. Yang W, Chen H, Jiang Y: Inhibitive effect of curcumin and amiloide on the fibrosis of rat hepatic stellate cells induced by oxidative stress. *Zhongyao 2003*, 26:795-8.

42. Zheng S, Chen A: Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. *Biochem J* 2004, 384:149-57.

43. Lin CF, Wong KL, Wu RS, Huang TC, Liu CF: Protection by hot water extract of Panax notoginseng on chronic ethanol-induced hepatotoxicity. *Phytother Res* 2003, 17:119-22.

44. Shi XF, Liu Q, Li L, Xu M: Effect of total saponin of Panax Notoginseng on liver fibrosis in rats. *Zhongguo Yiyu yu Linchuang* 2004, 20:12-4.

45. Park WH, Lee SK, Kim CH: A Korean herbal medicine, Panax notoginseng, prevents liver fibrosis and hepatic microvascular dysfunction in rats. *Lifesci* 2005, 76(15):1675-90.

46. Gong HY, Wang KQ, Tang SG: Effects of cordyceps sinensis on T lymphocyte subsets and hepatofibrosis in patients with chronic hepatitis B. *Hunan Xuey Xuebao* 2000, 25:248-50.

47. Liu YK, Shen W: Inhibitive effect of cordyceps sinensis on experimental hepatic fibrosis and its possible mechanism. *World J Gastroenterol* 2003, 9:529-33.

48. Ding J, Yu J, Wang C, Hu W, Li D, Luo Y, Luo H, Yu H: Ginkgo biloba extract alleviates liver fibrosis induced by CCl4 in rats. *Liver International* 2005, 25:1224-32.
50. Liu SQ, Yu JP, Chen HL, Luo HS, Chen SM, Yu HG: Therapeutic effects and molecular mechanisms of Ginkgo biloba extract on liver fibrosis in rats. Am J Chin Med 2006, 34:99-114.

51. Romano MR, Effert T, Serrano MA, Castano B, Macias RJ, Briz O, Marin JJ: Effect of artemisinin-artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system. Antiviral Res 2005, 67:85-93.

52. Tan YL, Goh D, Ong ES: Inhibitory effect of berberine on tert-butyl hydroperoxide-induced oxidative damage in rat liver. Arch Toxicol 2002, 76:646-70.

53. Janbaz KH, Gilani AH: Studies on preventive and curative effects of berberine on chemical-induced hepatotoxicity in experimental liver cirrhosis. Fitoterapia 2005, 76:25-33.

54. Hwang JM, Wang CJ, Chou FP, Tseng TH, Hsieh YS, Lin WL, Chu CY: Inhibitory effect of berberine on tert-butyl hydroperoxide-induced oxidative damage in rat liver. Antimicrob Agents Chemother 2000, 44:861-7.

55. Liu SQ, Yu JP, Chen HL, Luo HS, Chen SM, Yu HG: Therapeutic effects and molecular mechanisms of Ginkgo biloba extract on liver fibrosis in rats. Am J Chin Med 2006, 34:99-114.

56. Janbaz KH, Gilani AH: Studies on preventive and curative effects of berberine on chemical-induced hepatotoxicity in experimental liver cirrhosis. Fitoterapia 2005, 76:25-33.

57. Anis KV, Rajeshkumar NV, Kuttan R: Antiviral Res 2003, 61:762-9.

58. Yokozawa T, Ishida A, Kashiwada Y, Cho Ej, Kim Hy, Ikeshiro Y: Inhibitory effects of berberine on tert-butyl hydroperoxide-induced oxidative damage in rats. J Nutr Sci Vitaminol (Tokyo) 2000, 46:1-8.

59. Watanabe A, Obata T, Kaza S, Yamanaka O, Ikeda K, Reinach PS, Nakajima Y, Okada Y, Shirai K, Ohnishi Y: Genipin suppresses subconjunctival fibroblast migration, proliferation, and myofibroblast transdifferentiation. Ophthalmic Res 2006, 38(6):355-60.

60. Kuo CL, Chi CW, Liu TY: Anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 2004, 203:127-37.

61. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

62. Peng PL, Hsieh YS, Wang CJ, Hsu JL, Chou FP: Inhibitory effect of berberine on the invasion of human lung cancer cells via down-regulation of urokinase-plasminogen activator and matrix metalloproteinase-2. Toxicol Appl Pharmacol 2006, 214:8-15.

63. Kuo CL, Chi CW, Liu TY: The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 2004, 203:127-37.

64. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

65. Peng PL, Hsieh YS, Wang CJ, Hsu JL, Chou FP: Inhibitory effect of berberine on the invasion of human lung cancer cells via down-regulation of urokinase-plasminogen activator and matrix metalloproteinase-2. Toxicol Appl Pharmacol 2006, 214:8-15.

66. Wu TT, Isibashi A, Hasegawa M, Tsuchiya K: Inhibitory effect of berberine on tert-butyl hydroperoxide-induced oxidative damage in rat liver. Antimicrob Agents Chemother 2000, 44:861-7.

67. Liu SQ, Yu JP, Chen HL, Luo HS, Chen SM, Yu HG: Therapeutic effects and molecular mechanisms of Ginkgo biloba extract on liver fibrosis in rats. Am J Chin Med 2006, 34:99-114.

68. Janbaz KH, Gilani AH: Studies on preventive and curative effects of berberine on chemical-induced hepatotoxicity in experimental liver cirrhosis. Fitoterapia 2005, 76:25-33.

69. Hwang JM, Wang CJ, Chou FP, Tseng TH, Hsieh YS, Lin WL, Chu CY: Inhibitory effect of berberine on tert-butyl hydroperoxide-induced oxidative damage in rat liver. Arch Toxicol 2002, 76:646-70.

70. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

71. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

72. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

73. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

74. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

75. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

76. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

77. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

78. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

79. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

80. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

81. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

82. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

83. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

84. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

85. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

86. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

87. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

88. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

89. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

90. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

91. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.

92. Anis KV, Ramasamy NV, Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001, 53:763-8.
patients with type B chronic hepatitis. Int Immunopharmacol 1991, 13:41-6.

90. Suzuki M, Sasaki K, Toshizaki F, Oguchi K, Fujisawa M, Cyong JC: Anti-HBV virus effect of ursolic unshiu peel and its active ingredient noleatin. Am J Chin Med 2005, 33:87-94.

91. Suzuki M, Sasaki K, Toshizaki F, Oguchi K, Fujisawa M, Cyong JC: Anti-HBV virus effect of ursolic unshiu peel and its active ingredient noleatin. Am J Chin Med 2005, 33:87-94.

92. Ochi T, Kawakita T, Nomoto K: The protective effects of tradi tional Chinese medicine causing hepatotoxicity in patients with type B chronic hepatitis B infection: a 1-year prospective study. Zhongguo Zhongxiyi Jiehe Zazhi 2005, 25-6.

93. Cyong JC, Ki SM, Iijima K, Kobayashi T, Furuya M: The protective effects of traditional Chinese medicine causing hepatotoxici ty in patients with type B chronic hepatitis B infection: a 1-year prospective study. Zhongguo Zhongxiyi Jiehe Zazhi 2005, 25-6.

94. Liu CH, Hu YY, Xu LM, Liu C, Liu P: The protective effects of traditional Chinese medicine causing hepatotoxicity in patients with type B chronic hepatitis B infection: a 1-year prospective study. Zhongguo Zhongxiyi Jiehe Zazhi 2005, 25-6.

95. Liu CH, Hu YY, Xu LM, Liu C, Liu P: The protective effects of traditional Chinese medicine causing hepatotoxicity in patients with type B chronic hepatitis B infection: a 1-year prospective study. Zhongguo Zhongxiyi Jiehe Zazhi 2005, 25-6.

96. Liu CH, Hu YY, Xu LM, Liu C, Liu P: The protective effects of traditional Chinese medicine causing hepatotoxicity in patients with type B chronic hepatitis B infection: a 1-year prospective study. Zhongguo Zhongxiyi Jiehe Zazhi 2005, 25-6.

97. Liu CH, Hu YY, Xu LM, Liu C, Liu P: The protective effects of traditional Chinese medicine causing hepatotoxicity in patients with type B chronic hepatitis B infection: a 1-year prospective study. Zhongguo Zhongxiyi Jiehe Zazhi 2005, 25-6.